Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non-cash Items (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Non-cash Items for 3 consecutive years, with $4.0 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Non-cash Items changed N/A year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Sep 2024, changed N/A, and an annual FY2023 reading of $1.5 million, up 3047.71% over the prior year.
  • Non-cash Items was $4.0 million for Q3 2024 at Oramed Pharmaceuticals, up from $1.5 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $4.0 million in Q3 2024 and bottomed at $47000.0 in Q4 2022.
  • Average Non-cash Items over 3 years is $1.8 million, with a median of $1.5 million recorded in 2023.
  • Peak annual rise in Non-cash Items hit 3047.71% in 2023, while the deepest fall reached 3047.71% in 2023.
  • Year by year, Non-cash Items stood at $47000.0 in 2022, then skyrocketed by 3047.71% to $1.5 million in 2023, then surged by 170.38% to $4.0 million in 2024.
  • Business Quant data shows Non-cash Items for ORMP at $4.0 million in Q3 2024, $1.5 million in Q4 2023, and $47000.0 in Q4 2022.